|
US9732319B2
(en)
|
2010-12-22 |
2017-08-15 |
Fate Therapeutics, Inc. |
Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
|
|
WO2013066438A2
(en)
|
2011-07-22 |
2013-05-10 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
|
US20150166984A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting alpha-antitrypsin point mutations
|
|
CN120536341A
(zh)
|
2014-03-04 |
2025-08-26 |
菲特治疗公司 |
改良的重编程方法和细胞培养平台
|
|
AU2015298571B2
(en)
|
2014-07-30 |
2020-09-03 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
WO2016073955A2
(en)
|
2014-11-06 |
2016-05-12 |
President And Fellows Of Harvard College |
Cells lacking b2m surface expression and methods for allogeneic administration of such cells
|
|
US10626372B1
(en)
|
2015-01-26 |
2020-04-21 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
EP3294342A4
(en)
|
2015-05-08 |
2018-11-07 |
President and Fellows of Harvard College |
Universal donor stem cells and related methods
|
|
CN117737124A
(zh)
*
|
2015-10-16 |
2024-03-22 |
菲特治疗公司 |
用于诱导和维护基态多能性的平台
|
|
WO2017070632A2
(en)
|
2015-10-23 |
2017-04-27 |
President And Fellows Of Harvard College |
Nucleobase editors and uses thereof
|
|
US12642852B1
(en)
*
|
2015-11-04 |
2026-06-02 |
Fate Therapeutics, Inc. |
Genomic engineering of pluripotent cells
|
|
CN122146606A
(zh)
|
2015-11-04 |
2026-06-05 |
菲特治疗公司 |
用于诱导造血细胞分化的方法和组合物
|
|
JP6976960B2
(ja)
*
|
2015-11-27 |
2021-12-08 |
カーサリクス プロプライエタリー リミテッド |
遺伝子改変された細胞およびその使用
|
|
CA3303511A1
(en)
|
2016-01-26 |
2026-05-13 |
Cedars-Sinai Medical Center |
SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF
|
|
KR102614675B1
(ko)
|
2016-04-15 |
2023-12-19 |
메모리얼 슬로안 케터링 캔서 센터 |
유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법
|
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
|
WO2018027078A1
(en)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harard College |
Adenosine nucleobase editors and uses thereof
|
|
AU2017308889B2
(en)
|
2016-08-09 |
2023-11-09 |
President And Fellows Of Harvard College |
Programmable Cas9-recombinase fusion proteins and uses thereof
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
|
JP7215994B2
(ja)
|
2016-09-06 |
2023-01-31 |
ザ チルドレンズ メディカル センター コーポレーション |
人工多能性幹細胞由来の免疫細胞
|
|
KR20240007715A
(ko)
|
2016-10-14 |
2024-01-16 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
KR20240095477A
(ko)
*
|
2017-01-13 |
2024-06-25 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
면역조작된 만능 세포
|
|
AU2018219895C1
(en)
|
2017-02-09 |
2024-10-03 |
Indapta Therapeutics, Inc. |
Engineered Natural Killer (NK) cells and compositions and methods thereof
|
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
KR20190123328A
(ko)
|
2017-03-09 |
2019-10-31 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
암 백신
|
|
CN110914310A
(zh)
|
2017-03-10 |
2020-03-24 |
哈佛大学的校长及成员们 |
胞嘧啶至鸟嘌呤碱基编辑器
|
|
EP3601528A4
(en)
*
|
2017-03-20 |
2021-05-05 |
Washington University |
Cells and methods of uses and making the same
|
|
IL306092A
(en)
|
2017-03-23 |
2023-11-01 |
Harvard College |
Nucleic base editors that include nucleic acid programmable DNA binding proteins
|
|
CN110891967B
(zh)
*
|
2017-04-18 |
2025-03-14 |
富士胶片细胞动力公司 |
抗原特异性免疫效应细胞
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
US11566223B2
(en)
*
|
2017-06-01 |
2023-01-31 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cell preparation and uses thereof
|
|
MY200418A
(en)
|
2017-06-15 |
2023-12-25 |
Univ California |
Targeted non-viral dna insertions
|
|
EP3658573A1
(en)
|
2017-07-28 |
2020-06-03 |
President and Fellows of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
|
|
JP2020530997A
(ja)
*
|
2017-08-08 |
2020-11-05 |
サンガモ セラピューティクス, インコーポレイテッド |
キメラ抗原受容体媒介性細胞標的化
|
|
EP3441461A1
(en)
*
|
2017-08-11 |
2019-02-13 |
Baylor College of Medicine |
Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy
|
|
EP3676376B1
(en)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
|
CA3082251A1
(en)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
|
JP7621795B2
(ja)
*
|
2017-10-19 |
2025-01-27 |
セレクティス |
改善された免疫細胞療法のためのnk阻害物質遺伝子の標的指向遺伝子組み込み
|
|
GB201717524D0
(en)
*
|
2017-10-25 |
2017-12-06 |
Autolus Ltd |
Vectors
|
|
SG11202003798TA
(en)
|
2017-10-27 |
2020-05-28 |
Univ California |
Targeted replacement of endogenous t cell receptors
|
|
CN108118069A
(zh)
*
|
2017-11-06 |
2018-06-05 |
深圳市三启生物技术有限公司 |
新的模拟阿尔茨海默病的人诱导多潜能干细胞系及其用途
|
|
SG11202004529XA
(en)
*
|
2017-11-16 |
2020-06-29 |
Mogam Inst Biomedical Res |
Transformed human cell and use thereof
|
|
WO2019098361A1
(ja)
*
|
2017-11-20 |
2019-05-23 |
学校法人 慶應義塾 |
多能性幹細胞を用いた自殺遺伝子脳腫瘍治療薬
|
|
CN111556892A
(zh)
*
|
2017-12-08 |
2020-08-18 |
菲特治疗公司 |
使用增强的iPSC衍生的效应细胞的免疫疗法
|
|
US12406749B2
(en)
|
2017-12-15 |
2025-09-02 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
BR112020011017A2
(pt)
|
2017-12-22 |
2020-11-17 |
Fate Therapeutics, Inc. |
células efetoras imunes intensificadas e uso das mesmas
|
|
AU2019236288B2
(en)
*
|
2018-03-16 |
2025-06-05 |
Cedars-Sinai Medical Center |
Methods and compositions for inducible expression of neurotrophic factors
|
|
AU2019243315A1
(en)
*
|
2018-03-29 |
2020-09-24 |
Fate Therapeutics, Inc. |
Engineered immune effector cells and use thereof
|
|
WO2019226953A1
(en)
|
2018-05-23 |
2019-11-28 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
JP2021526838A
(ja)
*
|
2018-06-12 |
2021-10-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
幹細胞の操作によるinkt細胞に基づく既製の細胞療法
|
|
EP3820495A4
(en)
|
2018-07-09 |
2022-07-20 |
The Broad Institute Inc. |
RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
|
|
EP3824075A4
(en)
*
|
2018-07-17 |
2022-04-20 |
The Regents of The University of California |
CHIMERA ANTIGEN RECEPTOR T-CELLS DERIVED FROM IMMUNOMANIPULATED PLURIPOTENTS STEM CELLS
|
|
AU2019305585A1
(en)
*
|
2018-07-17 |
2021-01-28 |
The Regents Of The University Of California |
Cells differentiated from immunoengineered pluripotent cells
|
|
US20210275596A1
(en)
*
|
2018-07-20 |
2021-09-09 |
Cell2In, Inc. |
Application of gene profile for cells isolated using fresh-tracer
|
|
WO2020022512A1
(ja)
*
|
2018-07-26 |
2020-01-30 |
国立大学法人京都大学 |
外来抗原レセプター遺伝子導入細胞の製造方法
|
|
CN108913754A
(zh)
*
|
2018-07-26 |
2018-11-30 |
苏州呼呼健康科技有限公司 |
精子端粒长度的检测试剂、试剂盒及应用与检测方法
|
|
JP7541508B2
(ja)
|
2018-08-23 |
2024-08-28 |
サンガモ セラピューティクス, インコーポレイテッド |
操作された標的特異的な塩基エディター
|
|
US12378572B2
(en)
|
2018-09-07 |
2025-08-05 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
CN109136192A
(zh)
*
|
2018-09-20 |
2019-01-04 |
北京呈诺医学科技有限公司 |
一种iCAR-NK细胞的制备方法
|
|
CN113195724A
(zh)
*
|
2018-09-26 |
2021-07-30 |
新加坡国立大学 |
低免疫原性的工程化人类间充质基质细胞,制备方法和试剂盒
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
CN109266618B
(zh)
*
|
2018-10-18 |
2021-04-23 |
赛元生物科技(杭州)有限公司 |
能够靶向肿瘤细胞的巨噬细胞及其制备方法
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
EP3884041A2
(en)
|
2018-11-21 |
2021-09-29 |
Indapta Therapeutics, Inc. |
Methods for expansion of natural killer (nk) cell subset and related compositions and methods
|
|
CN113226340A
(zh)
|
2018-11-26 |
2021-08-06 |
恩卡尔塔公司 |
同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
|
|
KR20210094609A
(ko)
*
|
2018-11-28 |
2021-07-29 |
포티 세븐, 인코포레이티드 |
절제 레짐에 대해 저항성인 유전적으로 변형된 hspc
|
|
CN111424016A
(zh)
*
|
2019-01-09 |
2020-07-17 |
复旦大学 |
降低细胞免疫原性的诱导型多能干细胞系及建立方法
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
BR112021016046A2
(pt)
*
|
2019-02-15 |
2021-11-09 |
Editas Medicine Inc |
Células assassinas naturais modificadas (nk) para imunoterapia
|
|
SG11202108891QA
(en)
*
|
2019-02-15 |
2021-09-29 |
Harvard College |
Universal donor stem cells and related methods
|
|
WO2020171222A1
(ja)
*
|
2019-02-22 |
2020-08-27 |
国立大学法人 鹿児島大学 |
ヒト多能性幹細胞の安全領域に長い外来遺伝子を組み込み正常機能させる方法
|
|
KR20210137085A
(ko)
|
2019-03-05 |
2021-11-17 |
엔카르타, 인크. |
Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
|
|
WO2020191241A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
|
EP4332115A3
(en)
*
|
2019-04-03 |
2024-05-29 |
Precision Biosciences, Inc. |
Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
|
|
CN113906133A
(zh)
*
|
2019-04-11 |
2022-01-07 |
菲特治疗公司 |
工程改造的iPSC和免疫效应细胞中的CD3重建
|
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
US11162079B2
(en)
|
2019-05-10 |
2021-11-02 |
The Regents Of The University Of California |
Blood type O Rh-hypo-immunogenic pluripotent cells
|
|
US20220213434A1
(en)
|
2019-05-10 |
2022-07-07 |
The Regents Of The University Of California |
Modified pluripotent cells
|
|
CN110305899A
(zh)
*
|
2019-06-25 |
2019-10-08 |
华中农业大学 |
外源基因定点整合至gapdh基因下游的打靶载体构建方法及其应用
|
|
TW202115245A
(zh)
*
|
2019-06-27 |
2021-04-16 |
丹麥商諾佛 儂迪克股份有限公司 |
安全免疫隱形細胞
|
|
KR20220035190A
(ko)
*
|
2019-07-17 |
2022-03-21 |
페이트 세러퓨틱스, 인코포레이티드 |
면역 효과기 세포 조작 및 이의 용도
|
|
GB201911957D0
(en)
*
|
2019-08-20 |
2019-10-02 |
Adaptimmune Ltd |
Methods of producing haemogenic progenitor cells from pluripotent stem cells
|
|
US11116798B2
(en)
|
2019-09-05 |
2021-09-14 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
US11104918B2
(en)
|
2019-09-05 |
2021-08-31 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
US20220378831A1
(en)
*
|
2019-09-25 |
2022-12-01 |
Fate Therapeutics, Inc. |
Multi-targeting effector cells and use thereof
|
|
EP4041759A4
(en)
*
|
2019-10-07 |
2023-12-20 |
Fate Therapeutics, Inc. |
IMPROVED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTIVE CELL ENGINEERING AND ITS USE
|
|
WO2021072302A1
(en)
*
|
2019-10-10 |
2021-04-15 |
New York Stem Cell Foundation, Inc. |
Modified stem cells and methods of use thereof
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
EP4045648A4
(en)
*
|
2019-10-15 |
2023-11-22 |
The Regents of The University of California |
Transplanted cell protection via fc sequestration
|
|
EP4045539A4
(en)
*
|
2019-10-17 |
2024-03-13 |
Fate Therapeutics, Inc. |
Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
|
|
BR112022009181A2
(pt)
*
|
2019-11-25 |
2022-07-26 |
Univ Kyoto |
Sistema para prover um produto de célula t, métodos para produzir um produto de célula t, para construir um banco celular e uma coleção de produto de célula t e para prover um produto de célula t, banco celular, coleções de banco celular e de produto de célula t, e, produto de célula t
|
|
JP7879804B2
(ja)
*
|
2019-12-06 |
2026-06-24 |
フェイト セラピューティクス,インコーポレイテッド |
小化合物を使用するiPSC由来エフェクター免疫細胞の増強
|
|
NZ789406A
(en)
*
|
2019-12-27 |
2026-03-27 |
Zhaotai Immugene Biomedicine Hong Kong Ltd |
Engineered immune killer cell, preparation method therefor and use thereof
|
|
JP2023511965A
(ja)
*
|
2020-01-23 |
2023-03-23 |
カンステム バイオテック カンパニー リミテッド |
Off-the-shelf幹細胞および免疫細胞、それを含む薬学的組成物
|
|
WO2021173449A1
(en)
*
|
2020-02-25 |
2021-09-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Orthogonal safety switches to eliminate genetically engineered cells
|
|
WO2021202832A1
(en)
*
|
2020-04-03 |
2021-10-07 |
Progenitor Life Sciences |
Targeting tapasin and tap complex to improve cellular immune-compatibility
|
|
CA3177481A1
(en)
|
2020-05-08 |
2021-11-11 |
David R. Liu |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
|
US20230203445A1
(en)
*
|
2020-05-26 |
2023-06-29 |
Healios K.K. |
Hypoimmunogenic cells
|
|
WO2021251271A1
(ja)
*
|
2020-06-09 |
2021-12-16 |
帝人株式会社 |
Mhc-クラスi発現が抑制された細胞
|
|
KR20230040337A
(ko)
*
|
2020-06-19 |
2023-03-22 |
페이트 세러퓨틱스, 인코포레이티드 |
면역요법 사용을 위한 iPSC-유래 이펙터 세포 유형들의 조합
|
|
CN114276995A
(zh)
*
|
2020-09-28 |
2022-04-05 |
未来智人再生医学研究院(广州)有限公司 |
一种表达ctla-4阻遏分子的多能干细胞及其衍生物
|
|
CN114350612A
(zh)
*
|
2020-09-28 |
2022-04-15 |
未来智人再生医学研究院(广州)有限公司 |
表达靶向CTLA-4的shRNA/shRNA-miR的多能干细胞或其衍生物
|
|
IL301972A
(en)
*
|
2020-10-09 |
2023-06-01 |
Sana Biotechnology Inc |
Methods for activating safe killing mechanisms using the CD47–SIRPα blocking factor
|
|
WO2022093846A1
(en)
*
|
2020-10-26 |
2022-05-05 |
Arsenal Biosciences, Inc. |
Safe harbor loci
|
|
CN114507643A
(zh)
*
|
2020-10-29 |
2022-05-17 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-2的多能干细胞衍生物及应用
|
|
CN114457021A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达cd47抗体的多能干细胞及其衍生物与应用
|
|
CN114457027A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达Amyloidβ抗体的多能干细胞及其衍生物与应用
|
|
CN114457034A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-1阻断物的多能干细胞衍生物及其应用
|
|
CN114525256A
(zh)
*
|
2020-10-30 |
2022-05-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达Siglec-15阻断物的多能干细胞或其衍生物及应用
|
|
CN114457026A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达4-1bb激活型抗体的多能干细胞及其衍生物与应用
|
|
CN114517184A
(zh)
*
|
2020-10-30 |
2022-05-20 |
未来智人再生医学研究院(广州)有限公司 |
一种表达adipsin的多能干细胞或其衍生物及应用
|
|
CN114457024A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达IL-4Rα阻断物的多能干细胞或其衍生物及应用
|
|
CN114525257A
(zh)
*
|
2020-10-30 |
2022-05-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达Tim-3阻断物的多能干细胞或其衍生物及应用
|
|
CN114457028A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达cd38抗体的多能干细胞及其衍生物与应用
|
|
CN114525255A
(zh)
*
|
2020-10-30 |
2022-05-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-11的多能干细胞衍生物及其应用
|
|
CN114457029A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达vegf-a阻断物的多能干细胞或其衍生物及应用
|
|
CN114457033A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-6阻断物的多能干细胞衍生物及其应用
|
|
CN114525254A
(zh)
*
|
2020-10-30 |
2022-05-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达fgf-21的多能干细胞或其衍生物及应用
|
|
CN114457030A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达IgE阻断物的多能干细胞或其衍生物及应用
|
|
AU2021386370A1
(en)
|
2020-11-24 |
2023-06-22 |
Lyell Immunopharma, Inc. |
Methods for making, compositions comprising, and methods of using rejuvenated t cells
|
|
US11459372B2
(en)
|
2020-11-30 |
2022-10-04 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
IL303269A
(en)
|
2020-12-03 |
2023-07-01 |
Century Therapeutics Inc |
Genetically engineered cells and uses thereof
|
|
CN116981685A
(zh)
*
|
2020-12-03 |
2023-10-31 |
世纪治疗股份有限公司 |
基因工程化细胞及其用途
|
|
US20240277841A2
(en)
*
|
2020-12-11 |
2024-08-22 |
Purdue Research Foundation |
Human chimeric antigen receptor neutrophils, compositions, kits and methods of use
|
|
WO2022129472A1
(en)
*
|
2020-12-18 |
2022-06-23 |
Novo Nordisk A/S |
Safe immuno-stealth cells
|
|
CN114645018A
(zh)
*
|
2020-12-18 |
2022-06-21 |
未来智人再生医学研究院(广州)有限公司 |
一种表达cd38靶向抑制因子的多能干细胞及其衍生物与应用
|
|
TW202241935A
(zh)
|
2020-12-18 |
2022-11-01 |
美商世紀治療股份有限公司 |
具有可調適受體專一性之嵌合抗原受體系統
|
|
WO2022136215A1
(en)
*
|
2020-12-21 |
2022-06-30 |
Novo Nordisk A/S |
Safe immuno-stealth cells
|
|
CN114645021A
(zh)
*
|
2020-12-21 |
2022-06-21 |
未来智人再生医学研究院(广州)有限公司 |
一种表达靶向cd47抑制因子的多能干细胞及其衍生物与应用
|
|
CN114657134A
(zh)
*
|
2020-12-22 |
2022-06-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达靶向IgE的shRNA和/或shRNA-miR的多能干细胞或其衍生物
|
|
CN114657130A
(zh)
*
|
2020-12-22 |
2022-06-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达vegf-a靶向抑制因子的多能干细胞及其衍生物与应用
|
|
CN114717192A
(zh)
*
|
2020-12-22 |
2022-07-08 |
未来智人再生医学研究院(广州)有限公司 |
一种表达Amyloidβ靶向抑制因子的多能干细胞及其衍生物与应用
|
|
CN114657131A
(zh)
*
|
2020-12-22 |
2022-06-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达尿酸氧化酶的多能干细胞或其衍生物
|
|
CN114717193A
(zh)
*
|
2020-12-22 |
2022-07-08 |
未来智人再生医学研究院(广州)有限公司 |
一种表达靶向B7-H5的shRNA和/或shRNA-miR的多能干细胞或其衍生物
|
|
CN114657133A
(zh)
*
|
2020-12-22 |
2022-06-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达靶向IL-4 Rα的shRNA和/或shRNA-miR的多能干细胞
|
|
CN114657136A
(zh)
*
|
2020-12-22 |
2022-06-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达靶向PCSK9的shRNA和/或shRNA-miR的多能干细胞或其衍生物
|
|
CN114717232A
(zh)
*
|
2020-12-22 |
2022-07-08 |
未来智人再生医学研究院(广州)有限公司 |
表达irf-1靶向抑制因子的多能干细胞及其衍生物与应用
|
|
CN114657138A
(zh)
*
|
2020-12-22 |
2022-06-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达靶向B7-H4的shRNA和/或shRNA-miR的多能干细胞或其衍生物
|
|
EP4271798A1
(en)
|
2020-12-30 |
2023-11-08 |
CRISPR Therapeutics AG |
Compositions and methods for differentiating stem cells into nk cells
|
|
CN116940666A
(zh)
*
|
2020-12-31 |
2023-10-24 |
克里斯珀医疗股份公司 |
通用供体细胞
|
|
US11566230B2
(en)
|
2020-12-31 |
2023-01-31 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
KR102766602B1
(ko)
*
|
2021-02-05 |
2025-02-13 |
의료법인 성광의료재단 |
다능성 줄기세포 유래 조혈 내피세포를 이용한 유전자 편집된 세포의 제조방법
|
|
EP4298205A1
(en)
*
|
2021-02-23 |
2024-01-03 |
Poseida Therapeutics, Inc. |
Genetically modified induced pluripotent stem cells and methods of use thereof
|
|
CA3209946A1
(en)
*
|
2021-03-05 |
2022-09-09 |
Matthew Angel |
Engineered immune cell therapies
|
|
KR20230158044A
(ko)
|
2021-03-18 |
2023-11-17 |
남미 테라퓨틱스, 인크. |
암의 치료에 유용한 A2aR 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법
|
|
WO2022212514A1
(en)
*
|
2021-03-31 |
2022-10-06 |
Garuda Therapeutics, Inc. |
Pluripotent stem cell-derived hematopoietic lineages
|
|
US12617864B2
(en)
|
2021-04-12 |
2026-05-05 |
Medgene Therapeutics, Inc. |
Methods of activating and proliferating exhausted CD8 T cells, CD8 T cells with enhanced activity prepared by the same, and uses thereof
|
|
CA3216524A1
(en)
*
|
2021-04-12 |
2022-10-20 |
Medgene Therapeutics, Inc. |
A method of activating and proliferating exhausted cd8 t cells, cd8 t cells with enhanced activity prepared by the same, and use thereof
|
|
EP4323504A4
(en)
*
|
2021-04-16 |
2025-09-24 |
Hangzhou Qihan Biotech Co Ltd |
SAFE PORT LOCATION FOR CELLULAR ENGINEERING
|
|
WO2022272292A2
(en)
*
|
2021-06-23 |
2022-12-29 |
Editas Medicine, Inc. |
Engineered cells for therapy
|
|
US20240327794A1
(en)
*
|
2021-07-09 |
2024-10-03 |
Suprême |
Foodstuffs comprising cells differentiated from engineered oligopotent stem cells
|
|
WO2023288220A2
(en)
*
|
2021-07-12 |
2023-01-19 |
Children's Hospital Medical Center |
Differential cxcr4 expression on hematopoietic progenitor cells versus stem cells directs homing and long-term engraftment
|
|
WO2023004366A1
(en)
|
2021-07-21 |
2023-01-26 |
Aspen Neuroscience, Inc. |
Transposon-based modulation of gba1 and related compositions and uses thereof
|
|
US20250082686A1
(en)
|
2021-07-21 |
2025-03-13 |
Aspen Neuroscience, Inc. |
Aav-based modulation of gba1 and related compositions and uses thereof
|
|
CA3228692A1
(en)
*
|
2021-08-30 |
2023-03-09 |
Edward L. Perkins |
Tcd34 and other markers for identification and sorting of cells and for use as in vivo tracking assistant
|
|
MX2024003887A
(es)
|
2021-10-14 |
2024-07-09 |
Arsenal Biosciences Inc |
Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
|
|
IL312752A
(en)
*
|
2021-11-12 |
2024-07-01 |
Targetgene Biotechnologies Ltd |
Systems and methods for trans-modulation of immune cells by genetic manipulation of immune regulatory genes
|
|
WO2023116929A1
(en)
*
|
2021-12-24 |
2023-06-29 |
Hemacell Therapeutics Inc. |
Method for producing human induced pluripotent stem cells through homologous recombination and integrase-mediated recombination
|
|
KR20240128067A
(ko)
*
|
2021-12-29 |
2024-08-23 |
브리스톨-마이어스 스큅 컴퍼니 |
랜딩 패드 세포주의 생성
|
|
US20260000761A1
(en)
*
|
2022-01-19 |
2026-01-01 |
Nkarta, Inc. |
Engineered immune cells with enhanced potency and uses of same in immunotherapy
|
|
CN118843688A
(zh)
*
|
2022-03-04 |
2024-10-25 |
株式会社图尔金 |
低免疫原性干细胞、由干细胞分化或衍生的低免疫原性细胞及其制备方法
|
|
AU2023250649A1
(en)
|
2022-04-04 |
2024-11-14 |
The Regents Of The University Of California |
Genetic complementation compositions and methods
|
|
JP2025515095A
(ja)
*
|
2022-05-04 |
2025-05-13 |
センチュリー セラピューティクス,インコーポレイテッド |
Hla-eおよびhla-g導入遺伝子を用いて操作された細胞
|
|
WO2023220040A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified capsid for gene therapy
|
|
US20250302994A1
(en)
|
2022-05-09 |
2025-10-02 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified genome for gene therapy
|
|
US20250320521A1
(en)
|
2022-05-09 |
2025-10-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus compositions and methods for gene therapy
|
|
WO2024023802A2
(en)
*
|
2022-07-29 |
2024-02-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
|
|
EP4599051A2
(en)
*
|
2022-10-05 |
2025-08-13 |
Garuda Therapeutics, Inc. |
Erythroid lineages derived from pluripotent cells
|
|
WO2024102860A1
(en)
*
|
2022-11-09 |
2024-05-16 |
Shoreline Biosciences, Inc. |
Engineered cells for therapy
|
|
CN116334082B
(zh)
*
|
2023-02-15 |
2024-11-26 |
深圳市济因生物科技有限公司 |
一种CD16a基因敲除的NK细胞及其制备方法与应用
|
|
US12383615B2
(en)
|
2023-03-23 |
2025-08-12 |
Carbon Biosciences, Inc. |
Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods
|
|
WO2024196965A1
(en)
|
2023-03-23 |
2024-09-26 |
Carbon Biosciences, Inc. |
Parvovirus compositions and related methods for gene therapy
|
|
WO2024197552A1
(en)
*
|
2023-03-28 |
2024-10-03 |
Nuwacell Biotechnologies Co., Ltd. |
Genetically-modified pluripotent stem cells and derived natural killer cells and methods for producing the same
|
|
WO2025257133A1
(en)
|
2024-06-14 |
2025-12-18 |
Universität Zürich |
Gene-edited pluripotent stem cells for tissue engineering
|
|
WO2026030634A2
(en)
*
|
2024-08-01 |
2026-02-05 |
Senti Biosciences, Inc. |
Sustained transgene expression of imid-responsive peptide-suicide protein fusion polypeptides and uses thereof
|
|
WO2026072721A1
(en)
|
2024-09-25 |
2026-04-02 |
Carbon Biosciences, Inc. |
Parvovirus compositions and methods for gene therapy
|